CVE:TLT Theralase Technologies (TLT) Stock Price, News & Analysis C$0.16 -0.01 (-2.94%) (As of 09/6/2024 05:28 PM ET) Add Compare Share Share Today's RangeC$0.16▼C$0.1850-Day RangeC$0.16▼C$0.2152-Week RangeC$0.14▼C$0.28Volume532,496 shsAverage Volume118,823 shsMarket CapitalizationC$40.07 millionP/E RatioN/ADividend Yield1,757.58%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get Theralase Technologies alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Theralase Technologies Stock (CVE:TLT)Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology that accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. The company is based in Toronto, Canada.Read More TLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLT Stock News HeadlinesAugust 28, 2024 | finanznachrichten.deTheralase Technologies, Inc.: Rutherrin Increases Efficacy of Chemotherapy for Lung CancerAugust 28, 2024 | finance.yahoo.comRutherrin(R) Increases Efficacy of Chemotherapy for Lung CancerSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 22, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - TLT.WTAugust 21, 2024 | ca.finance.yahoo.comStocks in play: Theralase® Technologies Inc.August 21, 2024 | msn.comPharma stock Theralase paves way for in-home cancer treatmentAugust 21, 2024 | seekingalpha.comTheralase Technologies Inc. (TLTFF) Q2 2024 Earnings Call TranscriptAugust 21, 2024 | finanznachrichten.deTheralase Technologies, Inc.: Theralase Demonstrates Unique Ability to Activate Rutherrin With Diabetes DrugSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 21, 2024 | finance.yahoo.comTheralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes DrugAugust 16, 2024 | finance.yahoo.comTheralase Technologies Inc (TTX.SG)August 16, 2024 | msn.comThree micro-cap value stocks to hold for a decadeAugust 14, 2024 | finance.yahoo.comTheralase Technologies Second Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)August 6, 2024 | theglobeandmail.comTheralase Technologies: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (TLT)May 2, 2024 | finance.yahoo.comTheralase(R) Expands Clinical TeamApril 24, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Closes $CAN 750,000 Non-Brokered Private PlacementApril 5, 2024 | finanznachrichten.deTheralase Technologies Inc.: Theralase Granted Canadian Cancer Vaccine PatentApril 5, 2024 | finance.yahoo.comTheralase(R) Granted Canadian Cancer Vaccine PatentSee More Headlines Receive TLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theralase Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)12/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolCVE:TLT CUSIPN/A CIKN/A Webtheralase.com Phone+1-416-6995273FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-238.55% Return on Assets-81.88% Debt Debt-to-Equity Ratio20.58 Current Ratio1.21 Quick Ratio3.40 Sales & Book Value Annual SalesC$1.04 million Price / Sales38.52 Cash FlowC$0.01 per share Price / Cash Flow30.45 Book ValueC$0.01 per share Price / Book16.50Miscellaneous Outstanding Shares242,820,000Free FloatN/AMarket CapC$40.07 million OptionableNot Optionable Beta1.39 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Roger John Dumoulin-White B.Sc.P.Eng., President, CEO & DirectorMs. Kristina Hachey CPACFO & DirectorDr. Arkady Mandel DSc.M.D., Ph.D., Chief Scientific Officer & DirectorMr. David M. Groves B.APresident of World Trade DivisionDr. Terry Ruch DVMEquine Medical ConsultantKey CompetitorsQuipt Home MedicalTSE:QIPTProtech Home MedicalCVE:PTQProtech Home MedicalCVE:PHMHelius Medical TechnologiesTSE:HSMVentriPoint DiagnosticsCVE:VPTView All CompetitorsInsidersMatthew Thomas PerratonBought 900 shares on 1/4/2024Total: C$176.49 ($0.20/share)View All Insider Transactions TLT Stock Analysis - Frequently Asked Questions How have TLT shares performed this year? Theralase Technologies' stock was trading at C$0.18 at the beginning of 2024. Since then, TLT stock has decreased by 5.7% and is now trading at C$0.17. View the best growth stocks for 2024 here. How were Theralase Technologies' earnings last quarter? Theralase Technologies Inc. (CVE:TLT) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.01) EPS for the quarter. The business earned $0.10 million during the quarter. How do I buy shares of Theralase Technologies? Shares of TLT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Theralase Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theralase Technologies investors own include IMRIS (IMRSQ), Cross Timbers Royalty Trust (CRT), Aurora Cannabis (ACB), AGNC Investment (AGNC), InfraCap MLP ETF (AMZA) and Alliance Resource Partners (ARLP). This page (CVE:TLT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theralase Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theralase Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.